Subscribe
Photo Nature Travel / Shutterstock.com
27 May 2025NewsAmericasMuireann Bolger

Fed Circ refuses to stay Novartis feud with MSN over Entresto

Litigation concerns Novartis’ blockbuster $6bn heart failure drug, which has already expired | Indian generic company hoped to stay proceedings to prepare appeal against unfavourable decision.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Novartis and MSN feud intensifies after Fed Circ denies rehearing
27 March 2025   Both parties write to district court hours after Court of Appeals denies rehearing | MSN maintains that the Entresto patent should be delisted from the Orange Book | Novartis urges injunction to block generic version of heart treatment before regulatory gap closes.
Big Pharma
Novartis wins appeal in MSN clash over heart drug generic
14 January 2025   Federal circuit reverses district court’s ruling to revive combination patent | Novartis says patent has paediatric exclusivity expiring in July 2025.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Americas
Novartis and MSN feud intensifies after Fed Circ denies rehearing
27 March 2025   Both parties write to district court hours after Court of Appeals denies rehearing | MSN maintains that the Entresto patent should be delisted from the Orange Book | Novartis urges injunction to block generic version of heart treatment before regulatory gap closes.
Big Pharma
Novartis wins appeal in MSN clash over heart drug generic
14 January 2025   Federal circuit reverses district court’s ruling to revive combination patent | Novartis says patent has paediatric exclusivity expiring in July 2025.

More on this story

Americas
Novartis and MSN feud intensifies after Fed Circ denies rehearing
27 March 2025   Both parties write to district court hours after Court of Appeals denies rehearing | MSN maintains that the Entresto patent should be delisted from the Orange Book | Novartis urges injunction to block generic version of heart treatment before regulatory gap closes.
Big Pharma
Novartis wins appeal in MSN clash over heart drug generic
14 January 2025   Federal circuit reverses district court’s ruling to revive combination patent | Novartis says patent has paediatric exclusivity expiring in July 2025.

More features

Moderna entities must face infringement suits, UPC rules
Baker McKenzie adds London partner with ‘enviable’ expertise
‘Keep calm and carry on’: UK+ regime stays post-Brexit
As AI shakes up pharma and biotech, can patent law keep up?
UK court clears the way for Amgen and Samsung to launch biosimilars
SK Bioscience prevails over Pfizer in pneumococcal vaccine dispute
‘It’s going to be very different’: INTA CEO shares London meeting plans
'Scrap the billable hour': LSIPR joins INTA panel on gender diversity